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Abstract 
 
Introduction 
The 516G>T polymorphism in exon 4 of the CYP2B6 gene has been linked to 
increased plasma Efavirenz (EFV) levels.  EFV levels can predict therapeutic 
efficacy and are related to the likelihood of developing adverse central nervous 
system (CNS) effects.  The aims of this study were to a) determine the presence of 
the 516G>T and other possible CYP2B6 exon 4 polymorphisms in a South African 
group of HIV-infected individuals and b) to investigate the relationship between the 
EFV plasma concentrations, the CYP2B6  516G>T polymorphism and the 
occurrence of CNS related side effects in this group of patients. 
Methods 
Data from 80 patients are presented.  Genetic polymorphisms in exon 4 of the 
CYP2B6 gene were identified using PCR amplification of this region followed by 
sequencing of the amplification products. EFV levels were analysed by Ultra 
performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).  
Assessment of the presence of CNS related side effects following EFV initiation were 
elicited with the use of a questionnaire together with physical examination. 
Results    
Plasma EFV concentrations displayed high inter-individual variability amongst 
subjects with levels ranging from 94 µg /l to 23227 µg/l.   23 % of patients were TT 
homozygous for the 516G>T polymorphism.  These patients had significantly higher 
EFV levels vs. those with the wild (GG) genotype (p <0.05). Those who experienced 
no side effects had significantly lower EFV plasma concentrations vs. the group 
which experienced the most severe side effects (p< 0.05).   
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Conclusion 
The significant association between the 516G>T polymorphism and plasma EFV 
concentrations has been demonstrated in a South African cohort.  A rapid and 
sensitive method for the measurement of plasma EFV was developed and validated.   
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Chapter 1: INTRODUCTION 
 
1.1 General Introduction 
 
 
The South African government introduced the national rollout program of treatment 
of HIV (Human immunodeficiency virus) infected patients with highly active anti-
retroviral therapy (HAART) in April 2004.  Currently over 400 000 patients receive 
anti-retroviral therapy (ART) at South African state hospitals (1).  The first line 
therapy in treatment naïve patients consists of a combination of the non-nucleoside 
reverse transcriptase inhibitor (NNRTI) Efavirenz (EFV) and two nucleotide reverse 
transcriptase inhibitors (NRTI’s) – Stavudine and Lamivudine.   
 
In patients commencing therapy for the first time, the development of adverse effects 
may influence adherence and treatment success.  Significant side effects may be 
associated with all groups of anti-retroviral drugs.  Despite their recent introduction, 
in South Africa, ARV’s have been shown to significantly reduce morbidity and 
mortality in patients with HIV infection (2).  The ARV experience is relatively new to 
South Africa in comparison to many developed nations and studies looking at 
adverse effects of treatment and long-term treatment complications are only now 
beginning to emerge. 
 
Patients often differ in their response to identical therapies.  The reasons for this 
inter-individual variability in terms of drug related toxicity, drug levels and drug 
efficacy are multifactorial (3).  It involves differences in gender, metabolism, drug 
compliance, presence of underlying diseases, use of concomitant medications as 
well as genetic factors (3).  Genetic differences among individuals influence 
metabolism, distribution and elimination of drugs.  Clinically important genetic 
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polymorphisms, which influence drug metabolism and drug response, have typically 
been discovered on the basis of phenotypic differences among individuals from 
different populations.  Genotyping patients before drug therapy will help to better 
individualise therapy by enabling the identification of potential responders, non-
responders, or patients at increased risk of toxicity (3).   
 
Therapeutic drug monitoring (TDM) is useful to ensure that a patient has the 
appropriate blood levels of a particular drug to maximise therapeutic benefit and 
minimise toxicity.   The relationship between plasma levels of NNRTI’s as well as 
protease inhibitors has been shown to correlate with clinical antiviral effect in 
patients receiving HAART(4).  Since the active tri-phosphate metabolite of NRTI’s 
occurs intracellularly, the role of TDM for these agents is currently precluded (5). 
 
In the first chapter the relevance of genetic polymorphisms on Efavirenz therapy will 
be discussed.  The role of therapeutic drug monitoring in patients receiving Efavirenz 
therapy will also be reviewed. 
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1.2 Literature Review: 
 
1.1.1 Pharmacokinetics and pharmacodynamics  of Efavirenz 
 
Efavirenz and its metabolism 
 
Efavirenz belongs to the non-nucleoside reverse transcriptase inhibitor class of 
drugs utilised as part of HAART in the management of patients with HIV infection.  It 
acts by binding to reverse transcriptase non-competitively thus altering the function 
of the enzyme and preventing conversion of viral RNA to DNA (6).  Reverse 
transcriptase inhibitors are virustatic and thus do not eliminate HIV from the body.  
Although human DNA polymerase is less susceptible than the viral DNA polymerase 
to the pharmacologic effects of Efavirenz, the drug’s action may still account for 
some of its associated toxicity.  
 
Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-
4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one and has a molecular weight of 315.675 
g/mol.  Its empirical formula is C14H9ClF3NO2 and its structural formula is illustrated in 
Figure 1.1 (7). 
 
Figure 1.1.  Chemical structure of Efavirenz 
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The drug forms part of the triple therapy regimen and is taken orally as a single dose 
of 600mg at night.  Night time dosing is preferred in order to minimise the day time 
consequences of side effects such as hallucinations common in patients receiving 
Efavirenz therapy (7). 
 
Pharmacokinetics 
 
Efavirenz is absorbed orally, and is highly bound (> 99%) to plasma proteins, 
predominantly albumin.  The drug is also widely distributed in the central nervous 
system (CNS) (7). It is primarily metabolised by the cytochrome P450 isoenzyme, 
CYB2B6 in the liver (6) and to a lesser extent by the CYP3A4 enzyme (7). 
The CYP2B6 gene has been mapped to chromosome 19.  It is 28 kb long and 
consists of 9 exons (8).  The presence of several polymorphisms present in the gene 
coding for the enzyme may influence drug metabolism. CYP2B6 is primarily 
responsible for the hydroxylation of efavirenz to 8-hydroxyefavirenz and 8, 14- 
hydroxyefavirenz (6).  Efavirenz has a half-life of 52-76 hours after a single dose and 
40-55 hours after multiple doses(7), thus allowing for once daily dosing.  EFV and its 
metabolites are largely (60%) eliminated via bile through faeces (7).  Few studies 
have examined the influence of renal impairment on Efavirenz levels.  However the 
finding that less than 1% of Efavirenz is excreted unchanged in the urine suggests 
that the presence of renal impairment is unlikely to have an effect on EFV elimination 
(7). 
 
 
 
5 
 
Adverse effects 
Efavirenz is associated with several neuropsychiatric side effects such as 
hallucinations, mood changes, insomnia and headaches (Refer to Table 1.1)  
which are usually mild and generally short lived (weeks) (7, 9),  however, cases have 
been reported of individuals who have experienced significant depression or 
psychosis following initiation of Efavirenz which necessitate changing therapy (7).   
 
Table 1.1.  Reported side effects associated with Efavirenz (7) 
 
System  Side effects experienced 
Central and Peripheral 
Nervous System 
 
abnormal coordination, ataxia, cerebellar coordination 
and balance disturbances, convulsions, hypoesthesia, 
paresthesia, neuropathy, tremor 
 
Endocrine 
 
gynaecomastia 
 
Gastrointestinal 
 
constipation, malabsorption 
 
Cardiovascular 
 
flushing, palpitations 
 
Liver and Biliary 
System 
hepatic enzyme increase, hepatic failure, hepatitis 
 
Metabolic and 
Nutritional 
hypercholesterolemia, hypertriglyceridemia 
 
Musculoskeletal arthralgia, myalgia, myopathy 
 
Psychiatric aggressive reactions, agitation, delusions, emotional 
lability, mania, neurosis, paranoia, psychosis, suicide 
 
Respiratory dyspnea 
 
Skin and Appendages erythema multiforme, photoallergic dermatitis, Stevens-
Johnson syndrome 
Special Senses abnormal vision, tinnitus 
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Although previous centres (10) have reported central nervous system (CNS) side 
effects in >50% of patients following commencement of EFV therapy, no studies in 
South Africa have investigated EFV plasma concentrations and the incidence of 
CNS related side effects. 
 
In patients commencing therapy for the first time, the development of adverse effects 
may negatively influence adherence and treatment success.  Previous studies have 
shown that plasma EFV concentrations show large inter subject variability with a CV 
(coefficient of variance) of up to 118% (10).  Plasma concentrations of EFV predict 
therapeutic efficacy and are related to the likelihood of developing adverse CNS 
effects (9, 10).  Patients with EFV concentrations of > 4000 µg/l may experience 
neurological adverse effects more frequently, whilst those with plasma 
concentrations < 1000 µg/l appear to have a greater risk for emergence of selective 
drug resistance and treatment failure (10)  
 
Few studies have examined the adverse effects of long term EFV use.  Lochet et al 
investigated the long term effects by analysis of questionnaire responses from 174 
individuals after 6 months post initiation of EFV (11).  Their findings indicated the 
continued presence of moderate to severe neuropsychiatric symptoms in 23% of 
patients after a 3-month treatment period.   Their study also noted higher reporting of 
anxiety, depression and increased stress in those receiving EFV versus the control 
group.  6.3% of patients discontinued EFV therapy because of persistent or late 
onset neuropsychiatric symptoms (11).  Fumaz et al assessed adverse events, EFV 
plasma levels, quality of life, psychological status and adherence in patients on an 
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EFV based regimen vs. those on a protease inhibitor (PI) based regimen (12).  
These patients were followed-up for one year.  Quality of life was assessed using a 
questionnaire where each question was scored to give a final score from 0 to 100.  
EFV levels were also measured in these patients.   This study showed no 
association with EFV plasma levels greater than 4000 µg/l and the presence of 
neuropsychiatric symptoms in patients receiving longer term therapy. Overall there 
was no statistically significant difference in quality of life, adherence and 
psychological status between both groups. There were no reports of irrational 
thoughts or hallucinations amongst both groups of patients.  However on observation 
the patients on the PI regime showed decreased adherence with longer treatment 
periods (12).  Despite more neuropsychiatric abnormalities reported in the first four 
weeks of therapy in the EFV group vs. the PI group (54% vs. 27%), during this phase 
there was no difference in adherence between the two groups (12). 
 
1.3.2 The role of therapeutic drug monitoring in Efavirenz measurement 
 
Current consensus is that there is a definite role for TDM in the management of 
specific groups of patients receiving anti-retroviral therapy (4).  This is particularly so 
in the case of PIs and NNRTIs.  NRTI’s which are phosphorylated to their active 
metabolite intracellularly show poor correlation between plasma concentrations of 
parent drug and intracellular biologically active metabolites (5). TDM has a role to 
play in monitoring drug related toxicity, patient adherence, drug-drug interactions and 
in patients with co-infections and hepatic disease. In addition TDM may be useful in 
specific populations such as in paediatric and pregnant patients.  These populations 
undergo various metabolic, physiological and, in the case of children, also 
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developmental changes which may make prediction of drug concentrations difficult.  
TDM would allow for a more evidence based manner of adjusting dosage and 
regimens during these periods of transition.  Current PENTA (Paediatric European 
Network for the treatment of AIDS) guidelines recommend the use of TDM in young 
children receiving HAART (13). 
 
Increased plasma levels of Efavirenz have been associated with serious CNS side 
effects in those taking the drug and thus may affect patient compliance.   As 
previously stated,  plasma EFV  concentrations < 1000 µg/l have been associated 
with increased risk for emergence of  drug resistance (10). 
 
The concomitant use of drugs such as Flucanazole and traditional medicines (e.g. 
herbs such as St Johns Wort) can lead to significant drug interactions, affecting EFV 
levels (7).   In South Africa, with the high rate of co-infection with TB and 
HIV, the concomitant use of EFV and Rifampicin is common.  Rifampicin is a potent 
inducer of the CYP450 enzymes (14).  Plasma Efavirenz levels have been reported 
to be reduced by Rifampicin.  One study showed a decrease of 20-25% in area 
under the curve (AUC) levels for Efavirenz and no significant effect on the 
pharmacokinetics of Rifampicin in patients receiving both drugs (15).  Patients 
receiving anti-TB therapy and ART, who were less than 50 kg, had similar EFV 
concentrations as those patients receiving only HAART whilst EFV levels in patients 
> 50 kg were 50% less than levels found in patients receiving only HAART (15).  
Another study demonstrated a very large inter-subject variation (CV 157%) in plasma 
EFV levels in patients receiving concurrent rifampicin therapy but reported excellent 
clinical outcomes despite these variations in EFV levels (16). 
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TDM would be useful in this scenario to assess the effect of these drug-drug 
interactions on plasma EFV levels and to assist with dosage adjustment of Efavirenz.  
These factors make monitoring of ART a useful tool.                    
 
A common argument used against therapeutic monitoring of NNRTI’s is the fact that 
these drugs have a long half-life (40-50 hours) (7). Thus it is thought that plasma 
concentration of NNRTI’s would be adequate in most of these patients; however, 
high inter-individual variability in both concentration and patient response shown in 
various studies with NNRTI’s suggests a prominent role for TDM (17). 
 
Efavirenz measurement 
 
Various chromatographic methods have been utilized in the measurement of EFV.  
These include high performance liquid chromatography (HPLC), reverse- phase 
HPLC and liquid chromatography (LC) coupled to mass spectrometer (MS) or 
tandem MS (9, 10, 18).  These methods allow for simultaneous measurement of the 
parent drug, significant metabolites and other ARV’s.   The use of HPLC or LC-MS 
allows for multiple drugs to be measured.  This feature is of benefit in HIV infected 
patients receiving concomitant medication which can affect EFV levels such as for 
those receiving concomitant Rifampicin therapy.  Liquid chromatography refers to the 
separation of a specific material based on its affinity or interaction with the moving 
solvent, called the mobile phase, and the particles, called the stationary phase.  The 
stationary phase may be in a planar form or column form (where the column is 
packed with different types of chromatographic packing material which allows for 
separation of the compound of interest) (19).  High pressure or high performance LC 
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originally indicated that high pressure was used to generate the flow required for 
liquid chromatography in packed columns.  Ultra performance LC is a progression on 
HPLC, which uses smaller particles (sub-2-µm versus standard HPLC 5µm particles) 
as column packing material.  The use of smaller particles allows for significant 
increases in resolution, speed, and sensitivity in liquid chromatography (20). 
The tandem MS serves as the “detector system” for the UPLC.   The MS converts 
the molecules that enter into it into charged ions via various ionisation processes (for 
example chemical, electron spray ionisation). The ions are separated, identified, 
detected and measured according to their mass-to-charge ratios (m/z).   The relative 
abundance of each ion is plotted as a function of its m/z ratio and this is represented 
as a mass spectrum.  The ion with the highest abundance in the mass spectrum is 
assigned a value of 100%. Tandem MS allows for increased sensitivity and very high 
selectivity (19).   
 
However, these methods are often technically demanding, requiring extractions to be 
performed on samples prior to analysis, are only available in tertiary institutions and 
are not currently standardized.  In spite of initial capital costs of instruments 
consumables are inexpensive and extraction procedures can be modified to increase 
sample throughput. LC-MS has a very low interference rate which makes it highly 
suitable for identifying a specific drug in a plasma sample of a patient taking 
concomitant drug therapy.  HPLC-MS is considered a reference methodology for 
TDM due to its increased sensitivity and specificity. 
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1.3.3  The role of genetic polymorphisms and methods for their detection 
 
Cytochrome P450- B6 (CYP2B6) alleles 
 
CYP2B6 belongs to the enzyme family of cytochrome P450 mono-oxygenases.  Like 
most other members of the CYP family its function is to catalyse the oxidation of 
various organic substances including xenobiotics (drugs) (21).  The enzyme CYP2B6 
is involved in the metabolism of a variety of clinically important drugs such as 
Efavirenz and Nevaripine. 
 
Due to its extensive genetic polymorphism, CYP2B6 is characterized by wide inter-
individual variability in hepatic expression and activity (6).  The presence of several 
polymorphisms present in the gene coding for the enzyme may influence drug 
metabolism. Therefore in patients with polymorphisms causing decreased enzyme 
function, increased plasma levels and toxicity may occur .In patients with 
polymorphisms resulting in increased enzymatic activity, decreased drug levels and 
reduced therapeutic benefit may occur.  Previous studies have shown that the allelic 
variant 516G>T (located in exon 4) is associated with increased plasma drug levels 
(9, 22).  The allelic variant 516G>T (CYP2B6*6) was also shown to have increased 
prevalence amongst African Americans with studies quoting the frequency of this 
allele as 30-38% (9, 23).  Studies in African populations indicate a prevalence 
ranging between 36-60% (Table 2).   Klein et al showed a prevalence of close to 
50% for the 516G>T allele amongst a study population of Ghanaians (23).  A similar 
prevalence for this single nucleotide polymorphism (SNP), ranging from 36% (Sierra 
Leone) to 60% (Senegal) was reported by Mehlotra et al (24).  In a Zimbabwean 
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cohort Nyakutira et al demonstrated a frequency of 49% for the CYP2B6 516G>T 
variant (25).   A study in Zanzibar examining the effect of the CYP2B6 516G>T 
polymorphism on artemisinin (an anti-malarial drug) demonstrated a 9.7% frequency 
for the TT homozygotes (26).  
 
Other polymorphisms influencing CYP2B6 enzyme activity have been described.  A 
number of polymorphisms have been located in exon 9 of the CYP2B6 gene (22).  
Twenty-four non-synonymous SNPs and several SNPs, in the promoter region of the 
CYP2B6 gene have been reported (25).  Rotger et al recently described the 
presence of a polymorphism causing a premature stop codon resulting in a truncated 
CYP2B6 protein.   The CYP2B6*16 allele is defined by the presence of the 983T>C, 
together with the 785A>G polymorphism.  These SNPs are associated with reduced 
CYP2B6 protein expression.  The presence of polymorphisms may have an additive 
effect for example, 516G>T and 983T>C are associated with a five fold greater mean 
plasma EFV concentration (18). See Table 1.2 below for summary of important 
CYP2B6 SNPs. 
 
The relationship between a patient’s sex and their ability to tolerate antiretroviral 
drugs is increasingly being examined (27).  Differences in terms of incidence of side 
effects (22, 28) and response to treatment (29) have been demonstrated in various 
studies.  Mechanisms proposed to explain the above differences between males and 
females include weight, fat distribution, glomerular filtration rate (GFR) and the effect 
of sex hormones (27). 
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However evidence suggests that these differences between the genders may also 
be explained by different occurrences at the molecular level such as the presence of 
SNPs.  One study looking at CYP2B6 expression in liver tissue showed a 
significant difference between the two sexes.  They showed that CYP2B6 activity 
was below quantifiable limits in 7.1% of the female study population versus 20% of 
the male liver microsomes (30). 
Table 1.2.  Summary of studies evaluating the prevalence of CYP2B6 516 G>T and 
other polymorphisms 
Authors Population 
group 
Polymorphism Prevalence Effect on 
EFV level 
Klein et al 
(23) 
Ghana CYP2B6 516G>T 
variant 
50% Increased 
Mehlotra et 
al (24) 
Sierra Leone CYP2B6 516G>T 
variant 
36% Increased 
 Senegal CYP2B6 516G>T 
variant 
60% Increased 
Nyakutira et 
al(25) 
Zimbabwe CYP2B6 516G>T 
variant 
49% Increased 
Rotger et al 
(18) 
Various 
population 
groups in North 
America 
a)CYP2B6 917 
C>G (exon 6) 
 
b) CYP2B6 983 
T>C (exon7) 
 
c)CYP2B6 1132 
C>T (exon7) 
 
d) CYP2B6 1172 
T>A (exon8) 
 
e) CYP2B6 1459 
C>T (exon9) 
a) allele CG in 
black  patients 
1.3% 
b)  allele TC in 
black  patients 
18.75% 
c) allele CT in 
black  patients 
1.3% 
d) polymorphism 
not observed in 
black population  
e) allele CT in 
black  patients 
6.25 % 
 
 
Haas et al 
(9), Klein et 
al (23) 
African 
American  
1459C>T (exon 
9) 
1% Increased 
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This suggests that differences in plasma drug concentrations between the sexes 
may also be attributed to molecular differences in genetic expression and not only 
factors like body mass index (BMI). 
 
Methods for assessing enzyme and gene activity 
 
Possible differences in drug metabolizing enzyme activity may be investigated by 
either examining phenotype with the use of probe drugs or with genotype analyses of 
the enzyme of interest.  Bupropion is the probe drug commonly used to assess 
CYP2B6 activity (31).  The use of probe drugs is time consuming and tedious for the 
patient. 
 
Genotypic analysis of the CYP2B6 gene typically involves polymerase chain reaction 
(PCR) with either restriction fragment length polymorphism or sequencing analysis of 
PCR products.   PCR utilises the ability of DNA polymerase to synthesize a new 
strand of DNA complementary to a specifically chosen template strand.  As DNA 
polymerase can add a nucleotide only onto a pre-existing 3’-OH group, it requires a 
primer (reverse and forward) to which it can add the first nucleotide.  Nucleotides 
(dNTPs or deoxynucleotide triphosphates) – single units of the bases A, T, G, and C 
are essentially “building blocks” for new DNA strands that are added to the master 
mix.  The use of primers allows one to choose a specific genomic sequence to be 
amplified, in this case exon 4 of the CYP2B6 gene.  The PCR process involves the 
following steps: denaturation (the separation of complementary strands), annealing 
(attachment of primer to target sequence) and elongation (addition of base pairs to 
15 
 
form complete strands).  PCR allows for exponential amplification of initial DNA 
templates (32).   
 
Polymorphism detection using sequencing 
 
The initial Sanger method used for DNA sequencing is based on the principle of 
DNA replication.  The Sanger method utilises the ability of DNA polymerase to 
incorporate 2’ and 3” di-deoxynucleotides, nucleotide base analogues that lack the 3’ 
hydroxyl group.  The Sanger procedure requires a DNA template, a sequencing 
primer, DNA polymerase, nucleotides (dNTPs), di-deoxynucleotides (ddNTPs) and a 
reaction buffer (33). 
 
Four separate reactions are set up, each containing labelled nucleotides (fluorescent 
labels or radioactive labels) and either ddA, ddC, ddG, or ddT.  Addition of ddNTP 
results in chain termination whilst addition of a dNTP results in chain extension by 
DNA polymerase.  This process results in the formation of extension products of 
various lengths terminated with ddNTPS at their respective ends. These extension 
products can be separated and analysed by various methods including 
electrophoresis and mass spectrometry.  The ABI 3130XL sequencer used in this 
study utilises capillary electrophoresis, a process whereby the DNA fragments are 
separated in a narrow bore silica tube by size and charge under the force of an 
electrical field.  The sequencing process consists of five integral steps which are; 1). 
Template preparation 2). Cycle sequencing 3). Purification after cycle sequencing 4). 
Capillary electrophoresis and 5). Data analysis (33). 
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Newer genotyping methods include genotyping by matrix-assisted laser 
desorption/ionization–time of flight mass spectrometry (MALDI-TOF/MS). 
MALDI-TOF/MS utilises a soft ionization technique which allows for the analysis of 
various large organic molecules, proteins & polypeptides to be analysed. This 
technique combines high throughput with high accuracy.  This method may be used 
for rapid screening for SNPs, quantitative allele studies and for discovery of new 
polymorphisms (34). 
1.3 Objectives 
The aims of our study were three-fold 1) to investigate and describe polymorphisms 
present in exon 4 of the CYP2B6 gene in black HIV infected individuals, 2) to 
develop and validate a rapid method for determination of EFV in plasma to enable 
monitoring of drug levels in HIV-infected patients and 3) to investigate the 
relationship between the EFV plasma concentrations and the presence of CYP2B6 
exon 4 SNPs with the occurrence of CNS related side effects in this group of 
patients. 
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Chapter 2 :  MATERIAL AND METHODS 
2.1 Sample collection  
 
Specimens were collected from 100 Black South African patients attending the ARV 
clinic at the Charlotte Maxeke Johannesburg Academic Hospital.  Samples from 80 
patients were used. Twenty patients were excluded due to insufficient plasma 
volumes for UPLC-MS/MS analysis, poor DNA yields following extraction or technical 
problems with regards to sequencing.  Informed consent was obtained from all 
participants involved with the study (see consent form in Appendix B). Ethical 
approval for the study was obtained from the Research Ethics Committee, Faculty of 
Health Sciences, University of the Witwatersrand (refer to Appendix G).  10 ml of 
blood in EDTA tubes were collected from each patient. These samples were 
collected from patients 2- 4 weeks after initiation of Efavirenz therapy.  This time 
interval was chosen as plasma EFV levels take 6-10 days to achieve steady state 
concentrations (7).  It was also to ensure better recall of side effects experienced by 
patients following initiation of ARVs.  All patients received the same dosage of 
600mg EFV nightly.  The samples were separated by centrifugation at 5000 g for 10 
minutes (immediately) after collection.  Buffy coats were stored at -200 C until DNA 
extraction and plasma samples were stored at –700 C until the analysis for EFV 
levels was performed. Time of last dose was obtained by patient report. Patients who 
had not taken their EFV the night before or those who had missed more than two 
doses were excluded from the study. (Refer to Table 2.1 for further exclusion 
criteria).  
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The use of concomitant drugs and herbal medications, which are known to influence 
plasma EFV levels, were excluded with the aid of a questionnaire administered to all 
participants (refer to Appendix C).  The presence of abnormalities on a patient’s liver 
function test (LFT) (refer to Table 3) was also an exclusion factor because significant 
liver dysfunction can affect CYP 450 enzyme function (6).   
 
Table 2.1.   Exclusion criteria for study  
 
 
Pregnancy or breast feeding 
Previous or current psychiatric disease being treated by a medical practioner 
Non compliance (missed more than 2 doses in one month) 
Alcohol intake >4 units/day for male and > 3 units/day in females 
( 1unit = 8g of alcohol) (35) 
 
Patients taking drugs that potentially may interact with Efavirenz metabolism 
(as stated in drug manufacturer’s information sheet) 
 
Liver affectation as indicated by : 
a) Transaminases > 5-10x the upper limit of normal 
b) ALP > 5-10x the upper limit of normal 
c) Total bilirubin > 2.5-5x the upper limit of normal (36) 
 
 
LFTS, CD4 and viral load 
The LFTs, viral load and CD4 analyses are performed routinely on all patients 
commencing ARV therapy at the clinic.  LFTs were carried out by the NHLS 
Chemistry laboratory.  Samples were analysed on the Roche Modular automated 
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chemistry analyser.  All analytes contained in the LFT panel were measured by 
spectrophotometric methodology. 
Viral loads were measured in the Department of Haematology using the Roche 
COBAS AMPLICOR HIV-1 MONITOR version 1.5 Test and the CD4 counts were 
determined by using the PLG (PanLeucogating) methodology flow cytometry 
(Beckman Coulter) in the Department of Haematology Johannesburg Hospital.  
PanLeucogating involves the use of a combination of antibodies to CD45 and CD4 or 
CD8 to identify the total leucocyte population on the fluorescence flow cytometer.  
This method developed by Drs Glencross, Janossy and Jani allows for a more 
accurate CD4 cell count to be determined by a dual-platform method (37). 
 
On their initial visit to the clinic each patient was weighed and their height recorded 
using standard methodologies.  These were then used to calculate BMI for each 
patient in the study.  Case files were analysed with regard to documentation of 
common presumptive Efavirenz side effects and a questionnaire (refer to Appendix 
C) was administered to patients at two weeks post treatment initiation.  Treatment 
adherence was also assessed using patient files and patient disclosure.  
 
2.2 DNA extraction 
 
DNA was extracted from buffy coats using Invisorb Blood Mini Kit (Invitek, Germany).     
Procedure: 
1. Lysis of cells in buffy coat 
- 200ul of buffy coat sample was transferred to a 1.5 ml reaction tube.  
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- 200 µl of Lysis buffer A and 20 µl of proteinase K was added and the sample 
mixed and incubated at 56 ˚C for 10 minutes. 
 2. DNA binding 
      -  400 µl of binding buffer was to tube in step one and vortexed. 
      - The sample was loaded onto a spin filter, incubated for 1 minute, then          
centrifuged at 12000 g for 2 minutes. 
 3.  Washing 
     - The spin filter was placed into a new receiver tube, washed with 500 µl of 
Wash buffer 1 and centrifuged for 1 min at 10000g. 
- The filtrate was discarded and the spin filter placed in a new receiver tube. 
800 µl of wash buffer 2 was added and the sample was centrifuged at 10000g 
for 1 minute. 
- This filtrate was discarded and the spin filter placed in a new receiver tube 
and centrifuged at maximum speed for 4 minutes. 
4.  Elution of DNA 
- The spin filter was placed into a new receiver tube, 200 µl of pre-warmed 
Elution Buffer was added to centre of the filter, incubated and centrifuged for 1 
min at 10000 g 
The concentration and purity of extracted DNA was determined on a Nanodrop 
spectrophotometer  (Thermo Scientific, USA) by measuring the absorbance at a 
wavelength of 260 nm for concentration and 260/280 nm for purity.  
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2.3 Amplification of exon 4 of the CYP2B6 gene 
Exon 4 of the CYP2B6 was amplified using conventional PCR.   
Primer design 
 
Forward and reverse primers for exon 4 were designed using the published gene 
sequence on GenBank (accession number NM 000767) together with the 
GeneRunner 3.05 software (Hastings Software Inc.).  Primer selection was based on 
those primers with the most specific binding capacity, the lowest likelihood of primer 
dimer formation and non-specific binding, and similar melting temperatures.   The 
Basic Local Alignment Search Tool (BLAST) accessed at 
www.ncbi.nlm.nih.gov/blast, was used to align primer sequences to the known gene 
sequence to confirm that the primers would amplify the desired gene region (refer to 
Table 2.2).  The size of the amplicon was 518 base pairs (bp) long. 
 
Table 2.2.  Exon 4 primers 
Name Sequence Tm (melting temperature in ºC) 
Exon 4 forward 5’-TGTTGTAGTGAGAGTTCAATG-3’ 56 
Exon 4 reverse 5’-CTATCCCTGTCTCACCGTC-3’ 62 
 
 
 
22 
 
The PCR reaction was carried out with a 12.05 µl master mix consisting of:  
dNTPs (Bioline,US)   0.75  µl  (Total concentration 10 mmol/l)   
forward primer   0.25 µl ( concentration 100 pmol/µl) 
reverse primer   0.25 µl  ( concentration 100 pmol/µl) 
Taq polymerase   0.15 µl  (concentratioin  5 U/µl) 
( SuperTherm Gold DNA polymerase, US) 
 
Extracted DNA                     2 µl (concentration above 30 (µg / µl) 
Water     7.65 µl 
Total  volume                     12.05  µl    
 
PCR reactions were performed on the MyCycler thermal cycler (BioRad 
Laboratories, US) using the following programme: 
 
Table 2.3  PCR programme 
Temperature 
(˚C) 
Time  Number of cycles 
1.    94  (initial denaturation) 11 minutes 1 
2.    94  (denaturation) 40 seconds  
       56  (annealing) 25 seconds  
       70   (extension) 1 minute  
3.    70  (final extension) 10 minutes 1 
 
PCR products were run on 1 % agarose gels together with a 50bp DNA molecular 
weight marker (Generuler; Fermentas, Lithuania) and a negative control to detect 
any possible contamination.  1 % agarose gels were made with 0.5g agarose tablets 
35 
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( Bioline, UK) and 50 ml TBE (Tris, boric acid, EDTA) buffer (for composition refer to 
Appendix A).  Ethidim bromide (2.5 µl) was added to the gel mixture in order to 
visualise the PCR products under UV light (Gel-doc viewer, BioRad laboratories, 
Italy).   5 µl of sample from each PCR reaction was mixed with 2 µl of loading buffer 
(refer Appendix A for constituents), and loaded into separate lanes of the gel, run at 
100V for 30 minutes and visualised under UV light. 
 
2.4 Polymorphism detection using sequencing 
 
Amplicons were sequenced by Inqaba Biotech (South Africa).  Sequencing was 
performed using the ABI 3130XL sequencer which is based on capillary 
electrophoresis methodology.  
 
Sequences were analysed with the Sequencher 4.1.4 software (Genecodes, USA).  
The reference sequence used was that for the CYP2B6 gene (accession number NM 
000767).  Each patient’s forward and reverse sequences were aligned against the 
reference sequence and any SNPs in the patients.  Sequences were reviewed by the 
investigator with the aid of the Sequencher software. 
 
2.5 Measurement Plasma Efavirenz concentrations 
 
Sample preparation for analysis 
 
EFV was extracted using solid phase Weak Cation Exchange cartridges (WCX, 
Oasis-Microsep, Massachusetts, USA).  Solid-phase extraction (SPE) is a separation 
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process that utilises physical and chemical properties of compounds to isolate them 
from a complex mixture and thus in itself can also be considered a type of 
chromatography (19).  Knowledge regarding the chromatographic behaviour of the 
analyte of interest, and of other matrix components assists in the choice of proper 
sorbent and eluents.  The mechanism of separation employed by the WCX cartridge 
used, is based on ion-exchange principles and thus best suited to isolate compounds 
that are easily ionisable.  Cartridges can be either cation or anion exchangers and 
are further subdivided into weak or strong exchangers, depending upon the type of 
ionic group on their surface. Weak cation exchangers possess an acidic surface 
moiety such as a carboxylic acid that is ionised (negatively charged) at high pH but 
neutral at low pH whereas strong cation exchangers possess a moiety that remains 
ionised over the whole pH range (20).  The pKa of Efavirenz was found to be 10.2 
thus allowing for adequate recovery on the WCX cartridge (38).   
 
 
Preparation of solutions and standards 
 
 
Solutions required for sample extraction, and analysis on UPLC- MS/MS were 
prepared using commercially available HPLC reagent grade materials.  
 
Extraction procedure:  
- 200µl of plasma was used for analysis of the drug levels. WCX cartridges 
were conditioned with 1 ml Hydrochloric acid (HCl) solution (concentration 
1%) and 1 ml methanol (concentration 100%) before sample loading.  The 
HCl solution was made by dilution of 100% HPLC reagent grade HCl with 
Grade 1 water. 
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- 1 ml of  patient ‘s plasma was then loaded onto the cartridge  
- Vacuum pressure was exerted at a pressure of 10 kPa. 
- 1ml of HCL ( concentration 1%)  used  to wash  each cartridge 
- Collection tubes were discarded and new tubes were placed under each  
WCX cartridge 
- The  specimens  were then eluted with  1ml solution of 30% acetonitrile 
(which was made up by dilution of 100% HPLC reagent grade Acetonitrile with 
Grade 1 water)  
 
Instrumentation and UPLC- MS/MS conditions  
 
 
EFV plasma levels were measured by Ultra Performance Liquid Chromatography 
Quatro micro (UPLC-MS/MS), (Waters, Massachusetts, USA).   
Chromatographic separation was performed on an Acquity, (Waters, Massachusetts, 
USA) phenyl column 1.7µm (diameter of packing material) [2.1 (diameter of column) 
x 50mm (column length)].  The phenyl columns have a wide pH range and are 
suitable for separation of polar compounds (such as EFV) (29).  A guard column was 
used to protect the phenyl column from any particulate matter thus prolonging the life 
of the phenyl column. The chromatographic column used was stable for > 200 
injections.  This stability allows for cost reduction in running the assay. 
The mobile phase consisted of A: B at 30:70 (2 mM ammonium acetate with 1% 
formic acid: 100% Acetonitrile ).   
The mobile phase was made up in the following manner: 
A:  1. 2mM ammonium acetate (molecular weight 77.08 g/mol) solution- 
 0.308 g of ammonium acetate dissolved in 2 litres of Grade 1 water. 
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2. 1% formic acid – 100% (concentration w/v) was diluted with Grade 1 water to 
give a final solution of 1% formic acid. 
B: 100% HPLC reagent grade acetonitrile was used  
 
The mobile phase was run on an isocratic gradient with the analyte eluting within 
1.5min.  The column temperature was maintained at 50ºC throughout the runs.  
Injection volume for each sample was 10 µl. The instrument was operated in 
Electron spray ionization positive (ESI+) mode. The multiple reaction monitoring 
(MRM) transition used for EFV was m/z (mass to charge ratio) 357.7>316.3. Refer to 
the table 6 below for further details of UPLC–MS/MS settings. 
 
Table 2.4 .  UPLC–MS/MS  settings for EFV analysis 
Source  (ESCi+)  Settings 
Capillary (kV) 2.40 
Corona  (µA) 14.00 
ES cone (V) 25.00 
APCI cone (V) 30.00 
Extractor (V) 3.00 
RF lens (V) 0.0 
Source temperature (˚C) 120 
Desolvation temperature (˚C) 400 
Cone gas flow (l/hour) 50 
Desolvation gas flow (l/hour) 650 
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Table 2.4 .  UPLC–MS/MS  settings for EFV analysis continued 
 
 
Analyser  Settings 
LM 1 Resolution 10.0 
HM1 Resolution 8.0 
Ion energy 1 0.5 
Entrance 2 
Collision 15 
LM 2 Resolution 10.0 
HM 2 Resolution 8.0 
Ion energy 2 3.0 
Multiplier (V) 650 
Syringe pump  flow (µl/min) 10.0 
 
Calibrators and controls. 
 
Commercially available calibrator standards and controls were used. 
(Chromosystems Instruments and Chemicals GmbH, Munich, Germany).  3 
standards of the following values: standard 1 -1415 µg/l, standard 2 - 2830 µg/l and 
standard 3- 5661 µg/l were used for calibration.  The lypholised controls and the 
calibrators were made up to the designated manufacturer volumes using Grade 1 
reagent water.  Calibration curves and controls were run with every batch of patient 
specimens.  The correlation coefficient of the standard curves obtained on multiple 
days was consistently ≥0.98 (n=18).   
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Assay procedure  
 
 
Following sample extraction, 200µl of sample was placed in sampling vials which 
were then placed in the UPLC sampling system.  Standards were run initially to 
establish the calibration curve.  Once the curve was acceptable, quality control 
materials (Chromogen systems) at two levels i.e. one within the therapeutic 
reference range and a high value were run before patient samples.   Retention time 
for EFV was 0.72 min with total run time of 2 min.  
   
Method characteristics:  Limit of quantification, Recovery, Linearity,  Precision and 
accuracy 
 
An evaluation [Clinical and Laboratory Standards Institute (CLSI) protocol EP10] to 
assess recovery, assay precision and linearity was performed for validation.  Three 
levels of QC material at a low, mid (1:1 mixture of the low and high controls) and a 
high value were run in a specific sequence over 5 days.  This protocol examined 
specific performance parameters such as linearity, carryover, bias, recovery (39).   
 
Specimen stability 
 
Specimens were assessed for stability by comparing initial values to values following 
storage at room temperature, 2 to 8 degrees Celsius, at -20 degrees Celsius and at -
70 ˚C.   
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Specificity  
 
To assess the effect of Bactrim (a commonly used co- medication in patient with 
Acquired Immunodeficiency Syndrome) three patients’ plasma samples were spiked 
with Bactrim (concentration 1mg/ml) and then analysed on the UP-LCMS/MS.  
 
2.6 Assessment of EFV-related side effects 
 
A questionnaire adapted from one used in the AIDS Clinical Trials Group study 
A5095 (40) was administered to all participants.  Responses were scored in terms of 
frequency of side effects experienced and severity in terms of effect on daily 
activities.  The maximum score that could be obtained was 72 points.  Based on their 
questionnaires, subjects were grouped into those with no side effects (Group1), 
those with mild symptoms (1-12 points - Group2), with moderate symptoms (13-48 
points - Group3) and with severe side effects (> 48 points or presence of 
hallucinations or psychotic episodes - Group 4).  All subjects were also seen by the 
same doctor during this visit to assess for the presence of neuropsychological side 
effects.  
 
2.7 Data analysis 
The Online Encylcopedia for Genetic Epidemiology Studies 
(http://www.genes.org.uk/software/hardy-weinberg.shtml) was used to assess test 
whether the SNPs were in Hardy-Weinberg equilibrium.   The Hardy-Weinberg 
equilibrium states that over serial generations the genetic variation in a population 
will remain constant if there are no disturbing factors such as mutations, natural 
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selection and non random mating.  Thus genotype and allele frequencies will remain 
constant in a large population where there are no disruptive factors (41).  
Statistical analyses were conducted using Statistica 8 (Statsoft, Tulsa, USA).  
Plasma EFV levels were analysed across genotype groups using nonparametric 
analysis of variance (ANCOVA) using appropriate post hoc test for paired means.  
Regression analysis was performed to assess the influence of other possible 
confounders such as age, gender & BMI. 
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Chapter 3: RESULTS 
3.1  Patient results 
 
Data for 80 consecutive patients were analysed.  Twenty patients from the initial 100 
recruited were excluded due to insufficient plasma volumes for UPLC-MS/MS 
analysis, poor DNA yields following extraction or technical problems with regards to 
sequencing. The main characteristics of the study cohort are summarised in Table 
3.1. 
 
Table 3.1.  Demographic details of subjects 
 
 
  Male                  Female                        Total 
Number     20                       60                80 
Age (years) 
 
38.5 ±8.9           37.2±9.1              37.5±9.0 (n=80) 
   
BMI (kg/m2) 
                                                                     
21.4±2.3            23.9±3.8        
       
           23.3±3.6 (n=80) 
   
CD4 cell count                     
( x106 /l)                                  
162                    115 
(19-378)            (2-293) 
             128      
             (3-378) 
             (n=80) 
Viral load 
(copies/ml) 
7.25x104            8.9x103 
(150-3x106)          (39-3x106)                                                  
(n=20)               (n=56) 
            8.63 x103                            
(39-3x106) 
 (n=76) 
Side Effects (Yes %)  25                     13                   
(n=5)                 (n=8)       
        33 
           (n=13) 
*Figures stated as mean±1SD, or as median (range).  Reference range for CD4 
count (500-1500x 106/l) 
 
SNP results for CYP2B6 exon 4 
The genotype distribution and EFV levels were as follows: 36% (n=29) of patients 
were homozygous GG for the CYP2B6 516G>T polymorphism with); 23 % (n=18) of 
patients were characterised as homozygous TT, and 41% (n=33) of patients were 
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heterozygous GT. The frequency of the T allele was 43%.  (Refer to figure 2 for the 
PCR gel run and refer to figure 3 for sequencing chromatograms).  A previously 
unreported SNP was identified in one patient in the non-coding region of the 
CYP2B6 gene.  This SNP was a G>C point mutation 54 bases upstream of the 
CYP2B6 516G>T SNP in exon 4.  The patient was homozygous for the G allele 
CYP2B6 516G>T polymorphism, had a plasma EFV level of 6812 µg/l (therapeutic 
range 1000-4000 µg/l) and was characterised as having mild side effects following 
ARV initiation.  This SNP was not observed in other patients in this study.  The 
significance of this is currently, unknown.  
 
Figure 3.1  Amplicons for exon 4 of the CYP2B6 gene (of patients’ samples) run on a 
agarose gel.  *Arrow indicates 500 base pair marker of the molecular ladder. In lane 
1 is the molecular ladder, lanes 2 and 3 are the negative controls and in lanes 4-10 
are patient samples. 
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Figure 3.2a  Electrophoretogram showing a GG homozygous patient at the 516G 
position of exon 4 in the CYP2B6 gene (as indicated by the yellow arrows)  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2b   Electrophoretogram showing a TT homozygous patient at the 516G 
position of exon 4 in the CYP2B6 gene (as indicated by the yellow arrows) 
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The frequency of the allele, in the study population, was in Hardy-Weinberg 
equilibrium.  These results are similar to those of Nyakutira et al. who studied this 
particular SNP amongst a Sub-Saharan African population (25).     
 
Results for plasma EFV concentrations 
 
Plasma EFV concentrations in patients ranged from 94 µg/l to 23227 µg/l (median 
3980 µg/l), confirming the high inter-individual variability previously noted (10, 25) in 
patients receiving EFV therapy. (Refer to figure 3.3 for MRM chromatogram) 
 
However, only 51% of patients had EFV levels within the recommended 
concentration range of 1000 µg/l to 4000 µg/l (10).  The average time between last 
dose of EFV taken by patients and sample collection was 14.6±1.5 hours.  Efavirenz 
plasma levels were not significantly affected by sampling times.  Multivariate 
regression analysis demonstrated that gender, age, BMI and time of dosage did not 
significantly affect EFV levels with p >0.1. 
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Figure 3.3  The MRM chromatogram of EFV for a patient sample.  The MRM 
chromatogram for the transition 357.7>316.3 is shown in the larger square. The 
chromatogram in the smaller square illustrates the total ion chromatogram for that 
specimen run. 
 
 
Findings of relationship between 516G>T SNP and EFV concentrations 
 
The homozygous GG group had a median EFV plasma level of 2260 µg/l (range 94 
µg/l to 12957 µg/l); the homozygous TT, had a median EFV level of 7136 µg/l (range 
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1334 µg/l to 23227); and the patients that were heterozygous GT for the 
polymorphism had a median EFV level of 3857 µg/l (range 184 µg /l to 15581 µg/l).  
 
Interestingly, most (61%) of patients who were homozygous GG for the 516G>T 
polymorphism had EFV levels within the therapeutic range, whilst only 16% of those 
with the TT genotype had levels within this range.  Further analysis demonstrated 
that patients who were homozygous TT for the 516G>T polymorphism had 
significantly higher EFV levels than those with the GG genotype (p <0.05) (Refer to 
Figure 3.4).   
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Figure 3.4. Box and whiskers plot of median Efavirenz (EFV) plasma concentrations 
by CYP2B6-516 genotype  
*small boxes, median values; bars, interquartile ranges; whiskers, full range.  GG, 
homozygous genotype; GT, heterozygous genotype, TT homozygous genotype; --- 
Value between dashed lines represents therapeutic range 
 
(µg/l) 
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Results of Questionnaire 
 
 
85% of patients experienced some form of EFV-related side effects.  The majority of 
patients (56%) experienced mild symptoms.  Those who experienced no side effects 
had a significantly lower median EFV plasma concentration of 2666 µg/l 
(concentrations ranged from 102.3 to 4839.7 µg/l) compared to the group which 
experienced the most severe side effects with a median EFV plasma concentration 
of 14882 µg/l (concentrations ranged from 9825 µg/l to 23227 µg/l) (p< 0.05).  (Refer 
to Figure 3.5) 
 
 
 
Figure 3.5.  Bar graph illustrating the distribution of the severity of EFV related side 
effects amongst the different genotypes 
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The majority of patients, who did experience side effects following initiation of 
Efavirenz therapy, had mild symptoms with dizziness (55%) and headache (45%) as 
the two most frequent complaints.   No patients reported suicidal ideation whilst only 
5 % of patients reported having experienced hallucinations following initiation of EFV 
therapy.  These findings are in concordance with other studies reporting the side 
effect profile of EFV therapy (7, 9, and 10).  Figure 3.6 below shows the distribution 
for side effect distribution experienced by patients in the study. 
 
 
 
Figure 3.6  Bar graph illustrating side effect profile of patients on Efavirenz therapy 
 
At the1-month follow-up visit following initiation of therapy, the specific EFV-related 
side effects had resolved for all patients involved in the study.  33% (7 of 21) of all 
patients who reported severe and moderate EFV related side effects carried the TT 
% 
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genotype.  Patients homozygous for the TT genotype did show increased overall 
side effects as compared to those displaying the GG genotype, however this 
difference did not reach statistical significance (p=0.08) 
 
3.2 Method characteristics:  Limit of quantification, Recovery, 
Linearity, Precision and accuracy  
 
Intra-assay and inter-assay precision CV’s ranged from 2.8 to 10%, and 8 - 8.9%, 
respectively.  Overall bias was ≤ 5% with the mid level control (level at therapeutic 
range) displaying the best accuracy. Guidelines for TDM have recommended a 
between day coefficient of variation between 5% and 10% (42). Refer to Table 3.2 
below for the assay performance data for this study 
 
The extraction efficiency/recovery ranged from 83-118% (acceptable recovery 80 – 
120%), with mean recovery following extraction of 101%.  The assay was linear up to 
a concentration of  30630 µg/l.  The limit of detection for the assay was 85 µg/l.  No 
significant carryover or drift was observed.  
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Table 3.2  Assay performance data (EP 10 evaluation) 
RUN  REPLICATE LOW 
(units µg/l) 
Target value 
1105 µg/l.    
MID 
(units µg/l) 
Target value 
3306 µg/l.   
 
HIGH 
(units µg/l) 
Target value 
5507 µg/l.   
 
DAY 1 
 
 
 
 
 
     Mean Concentration 
1 
2 
3 
4 
5 
 
929 
1136 
1052 
 
 
 
1039 
3660 
3209 
3802 
3434 
2914 
 
3404 
5419 
5721 
5660 
 
 
 
5600 
DAY2 
 
 
 
 
 
      Mean Concentration 
1 
2 
3 
4 
5 
1082 
1091 
1211 
 
 
 
1128 
3321 
3783 
3505 
3150 
3062 
 
3364 
6020 
6155 
6483 
 
 
 
6219 
DAY3 
 
 
 
 
 
       Mean Concentration 
1 
2 
3 
4 
5 
1173 
1032 
1027 
 
 
 
1077 
2816 
3022 
3652 
3117 
3107 
 
3143 
6461 
6511 
6104 
 
 
 
6359 
DAY4  
 
 
 
 
 
       Mean Concentration 
1 
2 
3 
4 
5 
1000 
938 
975 
 
 
 
971 
3240 
3224 
3648 
3434 
3533 
 
3416 
5662 
5744 
5261 
 
 
 
5556 
DAY 5 
 
 
 
 
 
     Mean Concentration 
1 
2 
3 
4 
5 
1199 
1118 
1083 
 
 
 
1133 
3150 
3145 
3069 
3146 
2747 
 
3051 
5529 
5263 
5068 
 
 
 
5286 
    Mean concentration  
       (all days) 
 
 1070 3276 5804 
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Table 3.2  Assay performance data continued 
 
Within run CV for day 1 (%) 
  LOW 
 
10 
 
MID 
 
10 
 
HIGH 
 
2.8 
 
Within run CV for day 2 (%)  6.3 
 
8.5 
 
3.8 
 
Within run CV for day 3 (%)  7.68 
 
9.8 
 
3.5 
Within run CV for day 4 (%)  3.165 
 
5.3 
 
4.65 
 
Within run CV for day 5 (%)  5.27 
 
5.6 
 
4.37 
 
Mean inter-assay precision (CV)  8.25 
 
8.9 
 
8 
 
Average bias  35 µg/l.  
(-3%) 
30  µg/l.  
(1%) 
297 µg/l.  
(+5%) 
 
3.3 Specimen stability 
 
No significant changes in Efavirenz levels were observed in plasma that had been 
subjected to two freeze-thaw cycles.  See Table 3.3 for details on stability 
experiment. 
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Table 3.3.  Stability of plasma Efavirenz samples 
 
Storage condition 
Plasma  
EFV values 
 (units : µg/l) 
Recovery 
(%) 
Initial EFV plasma values 1) 4957 µg/l 
2) 5821 µg/l 
3) 11594 µg/l 
 
Stored at room temperature for 3 hours 1) 5271 µg/l 
2) 5419 µg/l 
3) 9864 µg/l 
1)106 % 
2) 93 % 
3)  85 % 
Stored at fridge temperature (2-8 C) for 24 hours 1) 4691 µg/l 
2) 5584 µg/l 
3) 10625 µg/l 
1) 95 % 
2) 96 % 
3) 92 % 
Stored at -20 C for 1 week 1) 4350 µg/l 
2) 5402 µg/l 
3) 11055 µg/l 
1) 88% 
2) 93 % 
3) 95 % 
Stored at -70 C for 3 months 1) 5097 µg/l 
2) 5712 µg/l 
3) 11405 µg/l 
1) 102 % 
2) 98 % 
3) 98 % 
 
3.3 Specificity 
 
The results obtained after the addition of Bactrim did not display any significant 
change with regards to the original Efavirenz concentrations. 
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Chapter 4:  DISCUSSION 
 
The current interest in pharmacogenomics and “personalised medicine” has gone 
from research to providing real clinical solutions for physicians and their patients.  
The increasing list of ARVs available together with the issues of drug-drug 
interactions, the presence of concomitant diseases, unpleasant and dangerous side 
effects of certain ARVs and patient non-compliance makes the treatment of HIV- 
infected patients highly complex.  Plasma EFV levels have been shown to be 
predictive of treatment success and the occurrence of adverse effects (9, 10).  The 
relationships between drug efficacy and lower virological failure rates when optimal 
drug concentrations are achieved have been demonstrated in a number of studies 
(10, 22, 23). 
 
The utilization of TDM together with relevant genotype analysis can potentially make 
the treatment of HIV infected individuals less complex and more effective.  The 
detection of polymorphisms affecting EFV concentrations may be used to direct 
therapy and dosage, thus minimizing toxicities.  Repeated exposure to sub-
therapeutic levels of EFV also increases the chance for the development of resistant 
viral strains and thus treatment failure (43).  Differences in metabolism of EFV play a 
role in determining effective plasma concentrations (9, 10).  Therefore SNPs in the 
CYP2B6 metabolizing enzyme resulting in decreased drug levels may select out for 
EFV resistance in certain patients whilst the expression of allelic variants such as the 
CYP2B6 516G>T polymorphism may lead to higher plasma levels, toxicity and 
eventually treatment failure.   The long half-life of EFV (42) suggests that treatment 
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interruption in patients carrying the TT genotype also selects for EFV resistance due 
to sub-therapeutic levels for extended periods. 
 
This study revealed the prevalence of the allelic variant CYP2B6 TT (poor 
metabolisers) to be 23% amongst our study population.  The percentage is very 
similar to the Adult AIDS Clinical Trials Group study by Haas et al (9), which reported 
a 20% prevalence of the TT genotype amongst their African–American cohort.  Both 
the prevalence of the SNP and correlating EFV plasma concentrations as reported in 
this study was similar to the published results of Nyakutira et al in Zimbabwe (25). 
 
The findings of this study echoed those of previous studies (10, 25) by 
demonstrating the association of significantly greater EFV plasma levels during ARV 
therapy with the CYP2B6 TT genotype.  In this study the statistically significant 
relationship between the occurrences of severe Efavirenz related side effects and 
increased plasma concentrations of the drug was observed.  
 
These findings although significant, do not allow for immediate use of this 
information in the prescribing of antiretrovirals nor the adjustment of dosage due to 
side effects.  It must be remembered that this polymorphism does not act 
independently and the presence of other polymorphisms and factors such as 
concomitant illnesses, use of polypharmacy and viral genotype also influence drug 
levels (43, 44).  Most of the pharmacogenomic studies investigating polymorphisms 
affecting the efficacy of EFV therapy have been performed on fairly small cohorts 
and larger studies are required to confirm their findings before these can be used to 
guide ARV therapy.  In nations like South Africa where the goal of adequate access 
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to antiretroviral therapy for all HIV-infected patients is still to be achieved, the added 
expense of pharmacogenomic genotyping may seem unrealistic.  However, TDM, 
which can be used to monitor patient adherence, manage ARV-related toxicities and 
detect treatment failure due to sub-therapeutic drug levels, appears to be fairly 
accessible, convenient and affordable method.  TDM for EFV using a LC-MS/MS 
method like that which is described in this study, allows for the accurate 
measurement of EFV and high throughput with a run time of only two minutes.   
 
To date this study has been the first to describe the presence of the CYP2B6 516 
G>T polymorphism in the South African black  population and the effect  this 
genotype has on EFV levels in South African black HIV infected individuals.  
 
Study limitations 
 
This was a small pilot study and larger studies in the South African population are 
needed to confirm these findings.  Pharmacokinetics shows that trough levels of 
drugs are the most useful in assessing efficacy and toxicity of the drug. The 
nighttime dosing of EFV results in difficulty obtaining trough doses.  The suggested 
therapeutic range of 1000 – 4000 µg/l is not based on trough levels but on levels 8-
20 hours post dosing (10).  Another limitation of this study is that pharmacokinetic 
modeling was not done to assess the possibility of reducing EFV dosage in those 
patients with the TT genotype.   Long term follow up of these patients to determine 
any correlation between the presence of the polymorphism and its influence on 
continued virological suppression in HIV–infected patients as well as obtaining 
personalized pharmacokinetic parameters will be useful 
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CONCLUSION 
 
This study has confirmed the presence of the CYP2B6 516G>T polymorphism in 
Black South African HIV patients.  The findings also show a significant relationship (p 
value <0.05) between the presence of the above polymorphism and elevated EFV 
plasma levels in HIV-infected patients receiving HAART.  Information gathered from 
studies like this one and those to follow will ideally assist in the formulation of 
protocols for the role of pharmacogenetics and monitoring of ARV levels for HAART 
in South Africa in HIV infected patients.  The use of pharmacogenetics and TDM to 
assist in the management of complex drug therapies such as HAART is an attractive 
option. Particularly as this study has revealed that a significant proportion of patients 
have EFV concentrations below the therapeutic range emphasizing that the 
measurement of EFV does have a role to play in their management in an 
environment of increasing incidences of treatment failure.   
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APPENDIX 
 
Appendix A.   
Constituents of loading buffer 
0.025 grams bromophenol blue 
0.025 grams xylene cyanol 
3 ml glycerol 
Make up to 10 ml with distilled water 
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Appendix B. CONSENT FORM 
Good morning sir/madam (patient) 
 
My name is Dr Verena Gounden and I am a doctor in the Department of Chemical 
Pathology.  I would like to welcome you and request your participation in our study.  
The information below explains the study and what will be needed from you should 
you agree to participate. 
 
Individuals infected with the human immunodeficiency virus (HIV) and receiving 
antiretroviral therapy (ART) may experience side effects which can make treatment 
unpleasant.  It has been shown in studies carried out in other countries that some of 
these side effects are related to differences in genes which may affect the level of 
the ARV medication in your blood.   We would like to look at the gene differences in 
the south African population and see if these affect levels of the drugs in blood and 
as well as side effects. 
 
To do this we must carry out blood tests. Bloods will be drawn by placing a needle 
into your arm and about 5ml of blood (1 teaspoon) taken for each tube. If you agree 
to participate in the study I will carry out blood tests on you before you begin 
treatment and then 2 weeks after the start of treatment.  The tests done on you will 
include a CD 4 count and a viral load.   These help in assessing your immune status 
as well as your response to treatment.  Genetic studies will include looking at the 
differences in the gene CYP2B6.   This is a gene that is involved in metabolizing 
several drugs including Stocrin which you will be receiving.  The blood taken will not 
be used for any tests other than those described. 
If we noted any blood changes that require a change in your treatment we will inform 
your doctor of these changes. 
 
Please note: Your participation in this study is voluntary and if you should choose 
not to participate this will in no way change your treatment at the clinic. Your identity 
will remain anonymous at all times and only your doctor will know then outcomes of 
the tests.  You will be identified for the purposes of this study by a unique patient 
number. 
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I (Dr Verena Gounden) have described the tests we wish to carry out and have 
explained the reasons for it. I have also asked whether there were any questions 
about the tests and have answered them the best I can. 
 
Date:                                  Doctor: 
 
 
 
 
 
 
 
 
 
 
Consent form (please sign this form) 
I agree to take part in the above clinical study. The procedures to be carried out have 
been explained to me. The possible discomforts, risks and benefits involved in taking 
part in the test have also been described to me. I understand that I can stop the test 
at any point. I also understand that if I have any questions concerning the test then 
the clinician will explain these to me  
 
 
Date:                                 Patient:    
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Appendix C. PARTICIPANT QUESTIONNAIRE  FOR EFAVIRENZ RELATED 
SIDE EFFECTS 
 
Thank you for your participation.  The purpose of this questionnaire is to help us 
evaluate the side effects you may have experienced since you started the ARV 
treatment.   
Did you experience any of the side effects listed below, after starting the ARV 
treatment?  Please circle your answer box.  
  
1.  Dizziness…………………………………………… YES(1)  NO (0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES(2)    
 
2.  Difficulty sleeping………………………………….. YES (1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)    
 
3.  Headache…………………………………………… YES(1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)     
 
4.  Difficulty concentrating…………………………….YES(1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)     
 
5.   Scary dreams ……………………………………. YES(1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
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b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES(2)  
 
6) Vivid dreams……………………………………..YES(1)                    NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES(2)      
 
7) Confusion…………………………………………. .. YES(1)  NO (0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)  
 
8) Did you feel sad/depressed (crying a lot, poor appetite, poor sleep) 
YES(1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)  
 
9) Nausea   …………………………………………….YES (1)  NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)  
 
10) Vomitting…………………………………………..YES(1)   NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)  
    
11)  Abdominal pain…………………………………..YES (1)   NO(0) 
 
a) How often did you experience this problem in one week?  ONCE  (0)               
TWICE (1)            THRICE  (2)               MORE THAN THREE TIMES A WEEK(3) 
 
b)  Did it interfere with your daily activities/work?                NEVER (0)                  
SOMETIMES (1)              MOST TIMES (2)  
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12) Rash…………………………………………………YES (1)  NO(0) 
 
15)  Hallucinations ( seeing things other people can't see)                         YES   
  NO 
    
16)  Suicidal tendencies requiring admission to hospital...                         YES
  NO 
      
17)  Mental disturbances that required admission to hospital.                     YES
  NO 
 
18)  Are you taking any other medication, herbal or traditional medicine  YES
  NO 
If YES what are the names 
 
19). Do you drink alcohol?     YES            NO 
if yes how many drinks do you have a day   1    /  2  /    3  /    4/  more than 4 
 
a“drink” is equivalent to… 
• 340 ml beer (1 can of beer) 
• 125 ml wine (half a normal glass, one wine glass) 
• 25 ml spirits (whisky, brandy, etc.) (1 shot) 
• 60 ml sherry 
• 25 ml liqueur (1 shot) 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix to questionnaire 
Points are allocated to each possible answer as indicated above 
   -No symptoms (0) 
   -Mild symptoms –with a total score of (1-12) 
   -Moderate symptoms- with a total score of (13-48) 
-Severe symptoms-a score of >48 or the presence of hallucinations, 
-suicidal tendencies or hospital admissions for mental disturbances 
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Appendix D: Article published in AIDS Research and Therapy 
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Appendix E: Poster presented at the IFCC conference –Brazil 2008 
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Appendix F. Abstracts: South African Pathology Congress, Cape Town 19-21 
July   2008 
 
Abstract 1: 
Plasma Efavirenz concentrations and CNS side effects in HIV-infected 
individuals.  
V. Gounden1, T. Snyman1, J George1 
1Department of Chemical Pathology, University of Witwatersrand, NHLS 
 
Introduction: Efavirenz (EFV), a non- nucleoside reverse transcriptase inhibitor 
(NNRTI), forms part of the first line therapy for many HIV infected individuals in 
South Africa. Central nervous system side effects have been reported in >50% of 
patients following commencement of EFV. Therapeutic drug monitoring (TDM) has a 
role to play in monitoring drug related toxicity, patient adherence, drug-drug 
interactions and in patients with co-infections and hepatic disease. Studies have 
shown that plasma concentrations of Efavirenz predict therapeutic efficacy and are 
related to the likelihood of developing adverse CNS effects.  
Aim: To investigate the relationship between the Efavirenz (EFV) plasma 
concentrations and the occurrence of CNS related side effects in patients that are 
compliant. 
Methods:  Plasma samples were collected from 100 patients at the Johannesburg 
Hospital ARV clinic. All patients received the standard dose of EFV 600 mg nightly. 
Specimens were collected 2-4 weeks after initiating EFV therapy.  Samples were 
taken the morning after the evening dose of EFV.  They were then stored at – 700 C 
until analysis by UPLC-MS/MS. A questionnaire eliciting the occurrence of CNS side 
effects was administered to all participating patients.  Responses were scored in 
terms of number of episodes of side effects experienced and severity in terms of 
effect on daily activities.  Patients were also seen by a doctor during this visit to 
assess neuropsychological side effects.  
Results: EFV concentration of samples ranged from 94,65 ug/l to 15581,5 ug/l. The 
mean plasma EFV concentration of the patient group with severe side effects was 
greater than the mean EFV levels in the patients with less severe side effects. 
Conclusion: Higher plasma EFV levels are associated with increased incidence & 
severity of CNS side effects. 
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Abstract 2: 
A rapid method of measuring plasma Efavirenz levels in HIV- infected 
individuals using LC–MS/MS methodology  
V. Gounden1, J. George1, T. Snyman1 
1Department of Chemical Pathology, University of Witwatersrand, NHLS 
 
Introduction: In many countries Therapeutic Drug Monitoring (TDM) of  antiretrovirals 
have become part of the national guidelines in the management of HIV-infected 
individuals.  Although not yet instituted in South Africa, TDM of ARVs will assist in 
both monitoring of drug toxicity and patient compliance. Increased plasma levels of 
Efavirenz (EFV) have been associated with serious CNS side effects.  Patients with 
efavirenz concentrations of > 4000ug/l may experience neurological adverse effects 
more frequently whilst those with plasma concentrations < 1000ug/l appear to have a 
greater risk for emergence of selective drug resistance and treatment failure 
Aim: To develop and validate a rapid method for determination of EFV in plasma to 
enable monitoring of drug levels in HIV-infected patients.  
Methods: Plasma samples from 100 patients attending the ARV clinic were collected 
the morning after the last dose of EFV (2-4 weeks after initiating therapy). EFV was 
analyzed by UPLC-MS/MS. Samples were extracted using solid phase Weak Cation 
Exchange cartridges (WCX, Oasis-Microsep). The samples were run on a Acquity 
1.7um 2.1 x 50mm phenyl column using a gradient of A: 2 mM ammonium 
acetate:100% acetonitrile(ACN) in a ratio of 70:30  B:100%  ACN returning to A 
(70:30) after 1.5 min. The MRM transition used for EFV was m/z 357.7.>316.3. The 
retention time was 0.72 min with total run time of 2 min. Validation of the method was 
done by EP10 protocol & using specific performance parameters  
Results: The limit of detection was 56 ug/l. Sample concentrations ranged  from 
94,65 ug/l to 15581,5 ug/l. Mean sample concentration was 4180.3 ug/l. The method 
has a CV of less than 15%. 
Conclusion:UPLC-MS/MS is a rapid method for analysis of plasma EFV 
concentrations 
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